<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03713892</url>
  </required_header>
  <id_info>
    <org_study_id>175MAD17021</org_study_id>
    <nct_id>NCT03713892</nct_id>
  </id_info>
  <brief_title>CKD-504 in SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects</brief_title>
  <official_title>Phase I Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, PK, PD of CKD-504 in Single SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single
      and multiple ascending oral doses of CKD-504 compared to placebo in healthy Korean and
      Caucasian adult subjects
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of CKD-504</measure>
    <time_frame>Day1, Day2, Day3, Day4</time_frame>
    <description>Peak Plasma Concentration (Cmax) of CKD-504</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of CKD-504</measure>
    <time_frame>Day1, Day2, Day3, Day4</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) of CKD-504</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Huntington Disease</condition>
  <arm_group>
    <arm_group_label>CKD-504</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>investigational Drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>investigational Drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-504</intervention_name>
    <description>orally administered once with investigational drug assigned on 1d morning with 240 mL of water</description>
    <arm_group_label>CKD-504</arm_group_label>
    <other_name>HDAC inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>orally administered</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult Korean or Caucasian aged 19 to 45 (inclusive) years, at the time of
             screening.

          -  Subjects weighing â‰¥ 50 kg with BMI between 18 and 27 kg/m2 (inclusive) at screening
             visit.

          -  Subjects who agreed to voluntarily participate in this study and comply with all the
             protocol requirements by signing informed consent form after being informed of the
             nature of this study and understanding all aspects of this study.

          -  Subjects who were deemed as eligible subjects by investigators on their physical
             examination, laboratory findings, and medical examination by interview.

        Exclusion Criteria:

          -  Subjects with a history of hypersensitivities to the drug, including investigational
             drugs or other drugs or with a history of clinically significant hypersensitivities.

          -  Subjects with a history of drug abuse or a positive urine screening for drug abuse.

          -  Subjects who have participated and taken investigational drug in any other clinical
             trial (including bioequivalence study) within three months prior to study drug
             administration.

          -  Subjects who have donated a unit of whole blood within 60 days or blood components
             within 30 days prior to study drug administration.

          -  Subjects judged ineligible for the study after a review of the clinical laboratory
             results by the investigator or for other reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min Ji Song</last_name>
    <phone>82-2-3149-7853</phone>
    <email>songmj@ckdpharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>In-Jin Jang</last_name>
    </contact>
    <investigator>
      <last_name>In-Jin Jang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 17, 2018</study_first_submitted>
  <study_first_submitted_qc>October 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2018</study_first_posted>
  <last_update_submitted>February 21, 2020</last_update_submitted>
  <last_update_submitted_qc>February 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histone Deacetylase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

